Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
These are my thoughts. I fear a private placement, and they are shorting in front of it
I am wonderng how many shares have been issued for this, and can this be reason for the low share price?
As partial consideration for, and as a condition to, the license, and to further align the strategic interests of the parties, the Company agreed to issue $1.0 million in shares of its common stock to SMI, in five installments through October 2017, at a price per share equal to the lesser of the average closing price for the five days prior to issuance and $1.25.
Don't know the real Robert Maxwell, but this Robert Maxwell is now our moderator.
Another distinct possibility.
I hope you are right.
It does seem like Shorty is having his way with it.
If its a cap raise, hope it is an overnight, and not a long drawn out affair.
It almost seems they are gonna do a private placement, and they are shorting it down to the price they want to pay.
They really need some news of some sort....
More from BLUE...
According to the researchers, bluebird execs are engaged in talks with regulators about getting the gene therapy approved for use.
https://endpts.com/bluebirds-gene-therapy-shows-promise-in-keeping-lethal-lorenzos-oil-disease-in-check/?utm_medium=email&utm_campaign=Thursday%20October%205%202017&utm_content=Thursday%20October%205%202017+CID_bb6794df4aad39908a9547129dabbfce&utm_source=ENDPOINTS%20emails&utm_term=Bluebirds%20gene%20therapy%20shows%20promise%20in%20keeping%20lethal%20Lorenzos%20Oil%20disease%20in%20check
bluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine
[Business Wire]
Business WireOctober 4, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for serious genetic diseases and T cell-based immunotherapies for cancer, today announced that interim data from an initial cohort of 17 patients in the ongoing Phase 2/3 Starbeam Study (ALD-102) evaluating Lenti-D™ investigational gene therapy in boys with cerebral adrenoleukodystrophy (CALD) were published in the New England Journal of Medicine (NEJM).
https://finance.yahoo.com/news/bluebird-bio-announces-publication-interim-190000886.html
Aren't you just a bit curious that there are 3.6 million shares out, and the whole 3.6 million is traded every week or so with no price appreciation? Seems like someone is shorting this daily.
I'm floored that you are such a pompous jackass, and I for one hope you leave as quickly as you came.
Great to have you back, Ice!
And congrats on your foresight.
My main point was that some large pharma, or any large corporation for that matter, get a bit uneasy if there is not a lot of capital on the balance sheet. We are still a very small company. I remember a few years ago when we got the animal health business from Amgen. They were not allowed to PR it, and released it on an 8K two days after Christmas. To boot, our CEO was a relative, his son I believe, of the founder of Amgen! The dilution would be meaningless, at this point!
It would also be gobbled up by the Tutes.
I think he meant the ceiling tiles in the cubicle....
I am beginning to think you really meant $11. LOLOL
I do not mind a raise here at all. For 4 million shares, you can get 35 to 40 million dollars. With them expanding, they would need cash for build-out, and this would give them 50 plus million.
Also helps for big clients thinking about using us, as the cash is there to fund expansion for their business.
Agree also..
But a successful trial and this changes my life because of averaging down. Also, Linda did bitch-slap him, and these guys are not used to that. So, he took his ball and went home. Blame him also for being a baby. Everyone blames LP for everything, but do we really have any idea what went on behind the curtain?
Woodford in control and we would have been bought out for a pittance.
I thought it at the time, and still think it today.
Woodford was dealing from the bottom of the deck.
Nice work, and a very nice find, thank you!
Well, then I reckon Exwannabe and China, among others, are doing their job extremely well in your case.
Welcome to the board.
Maybe it was this one?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134292688
Welcome to the board.
We, or at least CRYXorbust and myself appreciate your insights. Lolol
We still cannot get this right.
Woodward gave the company 95 Million.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133869517
Have another theory about the strength.
Regenerative medicine (immunotherapy) is very HOT now.
You have to pick a winner, but the big boys MRK BMS GLD cost a lot, and the upside is limited. There are smaller players, but they are not cheap either and they run the risk of failure and BK. Cryoport is a way for the tutes to be in the space with a good risk/reward, and you don't have to worry about drug failure, as they are supporting a lot of trials, and the price is cheap. We have also gotten some good press lately. They seem to be taking big positions here. But, as Rev said, we have to throw the profit takers out of our long term wagon on the way up!
Why do I get the sense that something is going on behind the curtain?
Up $.50 and volume of over 200,000 in an hour and 15 minutes.
The volume is staggering, given that we used to trade by appointment just 7 months ago. Just wondering out loud.
As Smith on Stocks analogy goes, we are selling shovels and picks to gold miners.
That is truly a great analogy!
I agree with your thoughts on this. Also think the Kite/Gilead approval will add a nice bump to the pps.
More good news for Cryoport.
https://finance.yahoo.com/news/cryoport-selected-support-potential-commercial-123000319.html
Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma's CAR-T Therapy Axicabtagene Ciloleucel
[PR Newswire]
PR NewswireSeptember 5, 2017
IRVINE, Calif., Sept. 5, 2017 /PRNewswire/ -- Cryoport (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), today announced that Kite Pharma has chosen Cryoport's industry-leading, advanced technology suite of cryogenic logistics solutions for the life sciences industry to support the potential commercial launch of its lead chimeric antigen receptor (CAR) T-cell therapy, axicabtagene ciloleucel (axi-cel), for the treatment of aggressive Non-Hodgkin Lymphoma (NHL). The engagement is structured to support Kite throughout the lifecycle of axi-cel.
Cryoport, Inc.
Cryoport, Inc.
Under the terms of the agreement, Cryoport will provide logistics support throughout the United States in accordance with Kite's plans for patient adoption of axi-cel. Cryoport's advanced cryogenic logistics solutions are designed to meet all of Kite's expanding cryogenic logistics requirements, including the use of its Cryoport Express® shippers, SmartPak II™ Condition Monitoring System, Cryoportal™ logistics platform, which includes chain-of-condition and chain-of-custody monitoring and, 24/7 logistics support. Being selected to provide commercial logistics support for Kite's lead therapy candidate marks a significant scaling in Cryoport's relationship with Kite and the opportunity for increased revenues for Cryoport.
Jerrell Shelton, CEO of Cryoport, stated, "Kite's CAR T-cell therapy for non-Hodgkin lymphoma is based on pioneering science which uses the patients' own immune cells to treat cancers. It offers hope to patients who previously had no other option left. We are delighted to be chosen to support the expected launch of this groundbreaking new therapy. Working with Kite to support its commercialization of axi-cel is a milestone for Cryoport. It also confirms our reputation as the logistics partner of choice to the life sciences industry's efforts in immunotherapies, which are leading the way in the development of a vast array of therapies."
In 2016, Cryoport and Kite expanded the agreement between the companies to support Kite's trials for its clinical stage therapies. Today, Cryoport provides cryogenic logistics support for six additional clinical stage therapies by Kite Pharma.
On an industrywide basis, Cryoport currently supports over 140 clinical trials for its biopharma clients, 17 of which are in Phase III.
About Cryoport, Inc.
Cryoport is the life sciences industry's most trusted global provider of cold chain logistics solutions for temperature-sensitive life sciences commodities, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport's solutions are used by points-of-care, CRO's, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport's proprietary Cryoport Express® Shippers, Cryoportal™ Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.
Cryoport is dedicated to
simplifying global cold chain logistics through innovative technology, unmatched monitoring and data capture and support, including consulting;
delivering the most advanced temperature controlled logistics solutions for the life sciences industry; and
providing vital information that provides peace of mind throughout the life of each logistics process.
For more information, visit www.cryoport.com. Sign up to follow @cryoport on Twitter at www.twitter.com/cryoport.
Very nice mention of Cryoport here.
http://www.marketwatch.com/story/novartis-car-t-therapy-was-the-first-approved-in-us-heres-how-to-invest-in-the-space-2017-08-31
Novartis’ CAR-T therapy was the first approved in U.S. — here’s how to invest in the space
By Emma Court
Published: Aug 31, 2017 10:37 a.m. ET
Companies that provide services and solutions to cell therapy companies will become invaluable, says Janney analyst Knight
Novartis’ NVS, +1.93% approval marks “the very early innings of a potential decade-long growth cycle,” said Janney analyst Paul Knight. Kite Pharma — which will be acquired by Gilead Sciences Inc. for $11 billion, in a deal made public earlier this week — should get its own CAR-T therapy approved by the end of November, he said.
For investors interested in “this burgeoning therapeutics field,” Knight recommended CryoPort Inc. CYRX, +6.72% , BioLife Solutions Inc. BLFS, -2.20% , Brooks Automation Inc. BRKS, +0.12% and Mesa Laboratories Inc. MLAB, +0.39% as ways to gain exposure, all of which he rates buy.
CryoPort, which provides cryogenic logistics solutions to the life sciences industry, had shares rise 4.1% in moderate Thursday morning trade.
The company has a three-year contract with Novartis to support Kymriah and believes that Kymriah alone will represent $8 to $10 million in annual revenue, Knight said.
In addition, clinical trials in regenerative medicine have grown substantially in recent years, with each trial worth about $50,000 a year to CryoPort, Knight said.
Hope this helps...
Small study, but results look impressive.
Kymriah Pivotal Study Results
The FDA approval of Kymriah is based on the results of the pivotal open-label, multicenter, single-arm Phase II ELIANA trial, the first pediatric global CAR-T cell therapy registration trial examining patients in 25 centers in the US, EU, Canada, Australia and Japan. In this Novartis-sponsored study, 68 patients were infused and 63 were evaluable for efficacy. Results show 83% (52 of 63; 95% confidence interval [CI]: 71%-91%) of patients who received treatment with Kymriah achieved complete remission (CR) or CR with incomplete blood count recovery (CRi) within three months of infusion. In addition, no minimal residual disease (MRD) - a blood marker that indicates potential relapse - was detected among responding patients. Median duration of remission was not reached (95% CI: 7.5-NE) 1.
The most common (>20%) adverse reactions in the ELIANA trial are cytokine release syndrome (CRS), hypogammaglobulinemia, infections-pathogen unspecified, pyrexia, decreased appetite, headache, encephalopathy, hypotension, bleeding episodes, tachycardia, nausea, diarrhea, vomiting, viral infectious disorders, hypoxia, fatigue, acute kidney injury and delirium. In the study, 49% of patients treated with Kymriah experienced grade 3 or 4 CRS, an on-target effect of the treatment that may occur when the engineered cells become activated in the patient's body. CRS was managed globally using prior site education and implementation of the CRS treatment algorithm. Within eight weeks of treatment, 18% of patients experienced grade 3 or 4 neurologic events. There were no incidents of cerebral edema. The most common neurologic events were encephalopathy (34%), headache (37%), delirium (21%), anxiety (13%) and tremor (9%).
http://archive.fast-edgar.com//20170830/AM22T22CZ22EF2WK22282WD2EP8QGZ22Z292/
I don't think a Pharma buys us.
I am sticking with someone like Amerisource Bergen.
If Kite/Gilead is approved, and maybe another like minded approval or two, the game will be afoot!
Senti,
Well done, as always. Thank You.
FDA ushers in a new era in cancer treatment with ‘historic’ CAR-T approval for Novartis
by John Carroll — on August 30, 2017 11:07 AM EDT
Updated: 11:20 AM
PDF
The FDA has approved the world’s first CAR-T therapy, giving a green light to Novartis for Kymriah (tisagenlecleucel) in what regulators themselves describe as an historic event.
The accelerated approval — about a month ahead of the PDUFA date — came through for certain pediatric and young adult patients with a form of acute lymphoblastic leukemia
None other than FDA Commissioner Scott Gottlieb did the honors in the FDA’s statement, noting:
“We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer. New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses. At the FDA, we’re committed to helping expedite the development and review of groundbreaking treatments that have the potential to be life-saving.”
A group of biopharma companies have been racing to this breakthrough point. Kite Pharma $KITE, newly bought out in a $12 billion deal by Gilead $GILD, is coming in a close second with its own application for axicel.
The next big move belongs to Novartis, the leader in the field, which will set the price on this therapy and likely those to come. Novartis’ investigators registered a game-changing 83% remission rate in its pivotal study.
CAR-T, though, is also associated with severe and potentially deadly side effects, including lethal instances of cytokine release syndrome with some patients dying from brain swelling in separate studies from the Novartis drug.
Regulators noted that they will require special training for anyone involved in delivering this therapy, while expanding the approval of Actemra (tocilizumab) to treat CAR T-cell-induced severe or life-threatening CRS in patients 2 years of age or older. “In clinical trials in patients treated with CAR-T cells,” the FDA reported, “69% of patients had complete resolution of CRS within two weeks following one or two doses of Actemra.”
This therapy, which is made using a patient’s own immune cells, won’t be cheap.
By its own reckoning, the UK’s tough watch dog on drug pricing has said that these drugs would be worth up to $649,000 a year, given the young patients it’s targeting first. Analysts, meanwhile, have pegged the price at anywhere from $400,000 to $750,000.
Novartis says it will reveal its price in a call later Wednesday. But in a statement the company said it “is collaborating with CMS to make an outcomes-based approach available to allow for payment only when pediatric and young adult ALL patients respond to Kymriah by the end of the first month. Future potential indications would be reviewed for the most relevant outcomes-based approach.”
Said Joseph Jimenez, CEO of Novartis:
“Five years ago, we began collaborating with the University of Pennsylvania and invested in further developing and bringing what we believed would be a paradigm-changing immunocellular therapy to cancer patients in dire need. With the approval of Kymriah, we are once again delivering on our commitment to change the course of cancer care.”
This approval marks a major shift in oncology, with a truly revolutionary approach to treating cancer. That hasn’t escaped the notice of big players and small, with a host of developers looking to do much better, more safely, with new drugs in the pipeline.
It’s a big day in the biotech world, but it’s just the official start date for a new era.
https://endpts.com/fda-ushers-in-a-new-era-in-cancer-treatment-with-game-changing-car-t-approval-for-novartis/?utm_medium=email&utm_campaign=ALERT%20FDA%20ushers%20in%20a%20new%20era%20in%20cancer%20treatment%20with%20historic%20CAR-T%20approval%20for%20Novartis&utm_content=ALERT%20FDA%20ushers%20in%20a%20new%20era%20in%20cancer%20treatment%20with%20historic%20CAR-T%20approval%20for%20Novartis+CID_b478855548eb40528cf6ab7b72a04479&utm_source=ENDPOINTS%20emails&utm_term=FDA%20ushers%20in%20a%20new%20era%20in%20cancer%20treatment%20with%20historic%20CAR-T%20approval%20for%20Novartis
Is there a Pulse here?
https://finance.yahoo.com/news/continental-acquire-indonesian-property-interest-173000776.html
PR Newswire•3 hours ago
Continental To Acquire New Indonesian Property Interest
JAKARTA, Indonesia, Aug. 28, 2017 /PRNewswire/ -- Continental
Entering a modal
Continental To Acquire New Indonesian Property Interest
[PR Newswire]
PR NewswireAugust 28, 2017
JAKARTA, Indonesia, Aug. 28, 2017 /PRNewswire/ -- Continental Energy Corporation (CPPXF) (the "Company") today announced that it has entered into a preliminary private placement agreement with PT ALT GME Bungalun Kariorang ("AGBK"), a privately owned Indonesian company. AGBK owns and operates a 100% interest in a special Indonesian production sharing joint cooperation contract with state-owned PT Pertamina EP known as a "KSO". The KSO has a term of 20 years to May 2036 and provides exclusive rights to conduct oil and gas exploration, exploitation, and production operations within an onshore area of 390,000 acres located on the east coast of Borneo island, named the "BK Block".
By taking up a new-issue private placement of AGBK's authorized share capital, the Company shall earn a 25% shareholding stake in AGBK, and shall also acquire exclusive rights from AGBK to off-take 100% of all future crude oil and natural gas produced by AGBK from the BK Block. Privately owned Indonesian company PT-ALT shall retain a 75% controlling interest stake in AGBK.
In accordance with the provisions of its KSO, AGBK paid a US$ 1,000,000 signature bonus and committed to expend a firm commitment amount of US$ 15,000,000 on geological, geophysical, and drilling work in the BK Block during the first 3 KSO contract years ending in May 2019. The Company will invest a total of US$ 4,000,000 to fund its 25% share of the bonus and of the firm commitment, to earn both its stake in AGBK and its rights to offtake future BK Block petroleum production.
AGBK shall use the entire investment proceeds exclusively for performing work within the BK Block in accordance with approved annual budgets as provided for in the KSO and firm commitment. The US$ 4,000,000 investment shall be treated by AGBK as a non-interest bearing advance from a shareholder. The Company shall be entitled to full reimbursement of the investment directly from BK Block oil or gas production "cost recovery" proceeds in the manner provided for in the KSO.
Closing of the placement is subject to and conditional upon final terms, conditions, and provisions to be set forth in four separate "Definitive Agreements"; 1) a "Placement Agreement", 2) a "Long Term Crude Oil Supply Agreement", 3) a "Long Term Natural Gas Supply Agreement", and 4) a "Shareholders Agreement". Closing is also subject to the Company delivering the first US$ 500,000 of the investment within 60 days of signature of Definitive Agreements, and also to AGBK acquiring the appropriate government permits to qualify the investment and the Company's 25% AGBK shares stake as a foreign direct investment and shareholding.
The placement and the Definitive Agreements are being negotiated on an arms-length basis notwithstanding the fact that a non-executive director of the Company is also the sole Director and CEO of AGBK. The director has no beneficial shares ownership in AGBK or in PT-ALT, the controlling holder of 75% of AGBK's shares. No fees of any kind are being paid to the director or to any third party intermediaries with regard to this transaction.
The BK Block is located in the Kutai Timur Regency of East Kalimantan Province, Indonesia on the northwest flank of the Kutai Basin, the prolific oil and gas producing geological region surrounding the Mahakam Delta. Notable oil producing companies in the Kutai include Chevron, Total, Vico (formerly HuffCo), and Pertamina. The BK Block does not currently produce oil on a commercial basis, but the Block includes over 100 oil wells drilled on oil fields that were producing over 2,000 BOPD oil before World War II. Most of the wells were sabotaged or destroyed during the war and commercial production was never restored. A few of the old wellbores that survived are still capable of flowing oil at the surface which is now collected and used by local residents. In addition to exploration and exploitation drilling rights, the KSO gives AGBK the rights to redevelop and restore these old fields to production.
AGBK's Director and CEO, Karsani Aulia said of the placement, "AGBK welcomes Continental as a new partner to the BK Block. We are confident our combined upstream operating experience and technical expertise will restore oil and gas production from the BK Block in the short term future. The block is known to produce a sweet 33o API gravity crude. This coupled with the highly prospective geological setting and the presence of never developed 1970's gas discoveries make the BK Block a very low drilling risk area. With the BK Block as our upstream platform we intend to pioneer and develop our shared vision with Continental of combining an upstream producing oil and gas property with a downstream small-scale refinery. This will reduce crude oil transport costs and enable us to efficiently supply much needed diesel and other motor fuels for plant gate sale to under supplied and growing local markets throughout the rapidly developing province of East Kalimantan."
The Company's CEO, Rich McAdoo stated, "In August 2016, the Indonesian government opened up the domestic crude oil refining and refined fuel distribution businesses to private sector companies allowing them to build, own and operate what the new regulation defines as "Small Scale Refineries" having a maximum capacity of 20,000 barrels per day. The government's intent with the new regulation is two-fold: 1) reduce crude oil transport costs from smaller, marginal, or declining fields and thereby incentivize the oil producers to increase production; and 2) provide much needed motor and marine fuels to the local regions surrounding the refinery and thereby reduce refined products imports and delivery costs. Continental's long history in operating upstream in Indonesia puts us in the ideal position to capitalize on this new downstream business opportunity. Our partnership with AGBK represents a first step for our Company in that direction. The long term offtake agreements with AGBK for any crude oil and natural gas we may find and produce will provide feedstocks for our initial small scale refinery."
On behalf of the Company,
Robert V. Rudman, CPA
Chief Financial Officer
I assume someone thinks they need to raise money to pay the 3 million in loans. They sure are following that script.
Agreed. My thoughts are the same as yours.
I wonder if Amerisource Bergen is doing their Due Diligence yet?
Kite projects revenue for 2017 to be between 40 and 50 million.
Your 2 billion of revenue is a tad high, no?
http://ir.kitepharma.com/releasedetail.cfm?releaseid=1014853
http://ir.kitepharma.com/releasedetail.cfm?releaseid=1036453
Diving deep into CAR-T, Gilead forges $12B buyout deal for Kite Pharma
by John Carroll — on August 28, 2017 06:52 AM EDT
Updated: 07:51 AM
PDF
Gilead has forged the big, transformational buyout deal that everyone in the industry has been waiting for.
Gilead $GILD has agreed to buy CAR-T pioneer Kite Pharma $KITE — which is likely just months away from its first approval — for $11.9 billion in cash.
The buyout, if it goes through, will instantly make Gilead a leader in adoptive cell therapy, going head-to-head against Novartis’ leading effort with CTL019.
Gilead agreed to forge the deal at a price of $180 a share, a relatively modest 29% premium of the company’s already swollen share price. Just three years ago, Kite went public with an IPO that initially priced at $17 a share. The buyout price represents a 960% increase on that.
Arie Belldegrun
Kite’s leading drug is axi-cel, which comes with a peak sales estimate hovering close to $2 billion a year. But the company has also been actively working on a slate of next-gen cancer therapies that promise to move beyond the initial re-engineering work with chimeric antigen receptors.
For Gilead, it’s a chance to forge a new business that can be reliably lined up next to its foundational work in HIV, where it continues to be an industry leader. Gilead paid $11 billion for Pharmasset to break into the hep C market. The company accomplished that task with flying colors, but after watching sales swell into megablockbuster territory, revenue has peaked and is expected to slide in coming years.
That combination of financial firepower — Gilead can easily fund this deal relying on its cash reserves — and a need to build the business put Gilead in a perfect spot to acquire Kite just as the biotech neared a major crossroad.
For Kite CEO Arie Belldegrun, the buyout marks the end of a major drive to create a company that could develop and market a personalized cell therapy. Kite has worked closely with the NCI’s Steven Rosenberg, the scientist who helped pioneer CAR-T therapies.
John Milligan, Gilead CEO
“The acquisition of Kite establishes Gilead as a leader in cellular therapy and provides a foundation from which to drive continued innovation for people with advanced cancers,” said John Milligan, Gilead’s president and CEO. “The field of cell therapy has advanced very quickly, to the point where the science and technology have opened a clear path toward a potential cure for patients. We are greatly impressed with the Kite team and what they have accomplished, and share their belief that cell therapy will be the cornerstone of treating cancer. Our similar cultures and histories of driving rapid innovation in order to bring more effective and safer products to as many patients as possible make this an excellent strategic fit.”
https://endpts.com/gilead-inks-deal-to-buy-car-t-leader-kite-pharma-for-11b-wsj/?utm_medium=email&utm_campaign=Monday%20August%2026%202017&utm_content=Monday%20August%2026%202017+CID_56d7a77f93b842dbf00bef8980bf9db2&utm_source=ENDPOINTS%20emails&utm_term=Diving%20deep%20into%20CAR-T%20Gilead%20forges%2012B%20buyout%20deal%20for%20Kite%20Pharma
Does I-Hub still have happy hour on Friday?
Just saw my answer on top of the page when I posted this!
My money is on the institutions.
Price is behaving exactly as you state about tutes establishing a position.
As far as revenues, Kite was given a pass on an adcomm meeting, which could mean they are approved as fast as Novartis. This would be huge.
https://endpts.com/fda-hands-kite-pharma-a-pass-on-axi-cel-panel-review-car-t-ready-to-launch/
I also expect revenue to pick up from this:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133549764
And this:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=133549764